NI201600093A - Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina - Google Patents
Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatinaInfo
- Publication number
- NI201600093A NI201600093A NI201600093A NI201600093A NI201600093A NI 201600093 A NI201600093 A NI 201600093A NI 201600093 A NI201600093 A NI 201600093A NI 201600093 A NI201600093 A NI 201600093A NI 201600093 A NI201600093 A NI 201600093A
- Authority
- NI
- Nicaragua
- Prior art keywords
- rosuvastatin
- composite formulation
- oral administration
- ezetimibe
- administration including
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2009—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
- A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
- A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/485—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Diabetes (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Se proporciona una formulación compuesta sólida para administración oral, incluyendo la formulación compuesta sólida: una parte de gránulos de ezetimibe, que incluye ezetimibe, teniendo dicho ezetimibe una distribución de tamaños de partículas en la que el tamaño medio de partículas d(0.9) para el 90% inferior es alrededor de 10µm o menos; y una parte de mezcla de rosuvastatina, que incluye rosuvastatina o una sal farmacéuticamente aceptable de la misma, y un método para preparar la formulación compuesta.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20130167156 | 2013-12-30 | ||
KR1020140071081A KR20150079373A (ko) | 2013-12-30 | 2014-06-11 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합제제 |
Publications (1)
Publication Number | Publication Date |
---|---|
NI201600093A true NI201600093A (es) | 2016-07-22 |
Family
ID=53791740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
NI201600093A NI201600093A (es) | 2013-12-30 | 2016-06-28 | Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina |
Country Status (25)
Country | Link |
---|---|
US (1) | US10434067B2 (es) |
EP (1) | EP3089739A4 (es) |
JP (1) | JP2017500303A (es) |
KR (2) | KR20150079373A (es) |
CN (1) | CN105873571B (es) |
AR (1) | AR098996A1 (es) |
AU (1) | AU2014374552B2 (es) |
CA (1) | CA2933178A1 (es) |
CL (1) | CL2016001654A1 (es) |
CR (1) | CR20160293A (es) |
DO (1) | DOP2016000159A (es) |
GT (1) | GT201600137A (es) |
MX (1) | MX2016008725A (es) |
MY (1) | MY187637A (es) |
NI (1) | NI201600093A (es) |
PE (1) | PE20161072A1 (es) |
PH (1) | PH12016501196A1 (es) |
RU (1) | RU2683937C2 (es) |
SG (1) | SG10201805657PA (es) |
SV (1) | SV2016005236A (es) |
TW (1) | TWI655944B (es) |
UA (1) | UA117685C2 (es) |
UY (1) | UY35932A (es) |
WO (1) | WO2015102400A1 (es) |
ZA (1) | ZA201603934B (es) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US10973790B2 (en) | 2015-10-30 | 2021-04-13 | Cancer Prevention Pharmaceuticals, Inc. | Eflornithine and sulindac, fixed dose combination formulation |
EP3243506A1 (en) | 2016-05-09 | 2017-11-15 | Adamed sp. z o.o. | Pharmaceutical composition |
JP2017210455A (ja) * | 2016-05-27 | 2017-11-30 | ニプロ株式会社 | エゼチミブ含有医薬組成物 |
CZ2016539A3 (cs) | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | Farmaceutická kompozice obsahující dvě rozdílné účinné látky a způsob její přípravy |
CZ2016538A3 (cs) | 2016-09-05 | 2018-03-14 | Zentiva, K.S. | Farmaceutická kompozice obsahující dvě rozdílné účinné látky |
KR101910902B1 (ko) * | 2016-11-03 | 2018-10-24 | 한미약품 주식회사 | 암로디핀, 로자탄 및 클로르탈리돈을 포함하는 약제학적 복합제제 |
KR102206535B1 (ko) * | 2016-11-29 | 2021-01-22 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 경구용 복합정제 |
JP6848469B2 (ja) * | 2017-01-20 | 2021-03-24 | ニプロ株式会社 | エゼチミブ含有医薬組成物の製造方法 |
JP7115825B2 (ja) * | 2017-06-28 | 2022-08-09 | 日医工株式会社 | エゼチミブ含有経口製剤及びその製造方法 |
JP2019014700A (ja) * | 2017-07-11 | 2019-01-31 | 大原薬品工業株式会社 | エゼチミブ含有口腔内崩壊錠及びその製造方法 |
JP6937195B2 (ja) * | 2017-09-01 | 2021-09-22 | 興和株式会社 | 医薬組成物 |
KR102569271B1 (ko) * | 2018-03-19 | 2023-08-23 | 한미약품 주식회사 | 에제티미브 및 로수바스타틴을 포함하는 약제학적 복합제제 |
GR1009727B (el) * | 2018-11-28 | 2020-04-14 | Elpen Αε Φαρμακευτικη Βιομηχανια | Μονολιθικη σταθερη φαρμακοτεχνικη μορφη ταχειας αποδεσμευσης εζετιμιμπης και ροσουβαστατινης |
BR112022001783A2 (pt) * | 2019-07-31 | 2022-03-22 | Tecnimede Soc Tecnico Medicinal Sa | Composições orais sólidas multiunitárias de liberação imediata, seus métodos e usos. |
WO2022045759A1 (ko) * | 2020-08-25 | 2022-03-03 | 주식회사 대웅제약 | 고혈압 및 고콜레스테롤혈증을 치료 또는 예방하기 위한 단일 제형의 약학 조성물 |
CN112999178A (zh) * | 2021-03-01 | 2021-06-22 | 乐普制药科技有限公司 | 一种依折麦布匹伐他汀钙复方双层片剂 |
GB2622822A (en) * | 2022-09-28 | 2024-04-03 | Novumgen Ltd | A rapidly disintegrating tablet of rosuvastatin and its process of preparation |
Family Cites Families (28)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2648897B2 (ja) | 1991-07-01 | 1997-09-03 | 塩野義製薬株式会社 | ピリミジン誘導体 |
DE59409631D1 (de) | 1993-07-15 | 2001-02-15 | Hoffmann La Roche | Pharmazeutische Kombination, die einen Hemmer des Renin-Angiotensin-Systems und einen Endothelin-Antagonisten enthält |
US5631365A (en) | 1993-09-21 | 1997-05-20 | Schering Corporation | Hydroxy-substituted azetidinone compounds useful as hypocholesterolemic agents |
EP1347987B1 (en) | 2000-12-20 | 2004-10-13 | Schering Corporation | Sugar-substituted 2-azetidinones useful as hypocholesterolemic agents |
KR100596257B1 (ko) | 2001-01-26 | 2006-07-03 | 쉐링 코포레이션 | 스테롤 흡수 억제제를 포함하는 조성물, 및 페록시솜 증식인자-활성화 수용체 활성화제와 스테롤 흡수 억제제를 포함하는 조성물 및 조합물 |
JP2005501861A (ja) | 2001-08-22 | 2005-01-20 | アベンティス・ファーマ・ドイチユラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | 1,4−ベンゾチエピン1,1−ジオキシド誘導体と他の活性物質との組合わせ剤及びそれらの使用 |
BRPI0412557A (pt) | 2003-07-28 | 2006-09-19 | Reddys Lab Inc Dr | forma de dosagem farmacêutica de eventos cardiovasculares |
MX2007012253A (es) | 2005-04-04 | 2007-12-07 | Univ Pontificia Catolica Chile | Uso de ezetimibe para la prevencion y tratamiento de calculos de colesterol en la via biliar. |
US7737155B2 (en) | 2005-05-17 | 2010-06-15 | Schering Corporation | Nitrogen-containing heterocyclic compounds and methods of use thereof |
US20070275052A1 (en) * | 2006-05-24 | 2007-11-29 | Glenmark Pharmaceuticals Limited | Pharmaceutical compositions containing sterol inhibitors |
US20130190487A1 (en) | 2007-01-24 | 2013-07-25 | Krka | Process for the preparation of ezetimibe and derivatives thereof |
EP2120882A2 (en) | 2007-02-23 | 2009-11-25 | Krka | Pharmaceutical composition containing a cholesterol absorption inhibitor |
AU2008281640A1 (en) | 2007-07-27 | 2009-02-05 | Cipla Limited | Pharmaceutical compositions and process for making them |
WO2009024889A2 (en) * | 2007-08-21 | 2009-02-26 | Ranbaxy Laboratories Limited | Pharmaceutical composition comprising a hmg-coa reductase inhibitor and ezetimibe |
CN102112440A (zh) | 2008-05-30 | 2011-06-29 | 武田药品工业株式会社 | 杂环化合物 |
DK2306982T3 (en) | 2008-06-27 | 2015-04-20 | Abdi Ibrahim Ilac Sanayi Ve Ticaret Anonim Sirketi | Pharmaceutical compositions of rosuvastatin calcium |
PL2229938T3 (pl) * | 2009-03-13 | 2012-09-28 | Sanovel Ilac Sanayi Ve Ticaret As | Kompozycje ezetymibu |
US20110196383A1 (en) | 2009-05-05 | 2011-08-11 | Atherolysis Medical, Inc | Atherosclerotic Plaque Dissolution Composition |
EP2448919A2 (en) | 2009-07-02 | 2012-05-09 | Mahmut Bilgic | Solubility and stability enchancing pharmaceutical formulation |
TR201009397A2 (tr) | 2010-11-11 | 2012-05-21 | Bi̇lgi̇ç Mahmut | Rosuvastatin içeren farmasötik bileşimler. |
EP2566465A2 (en) | 2010-05-04 | 2013-03-13 | Mahmut Bilgic | Stable rosuvastatin formulations |
KR101248804B1 (ko) * | 2010-05-14 | 2013-03-29 | 한미사이언스 주식회사 | HMG-CoA 환원효소 억제제 및 이베살탄을 포함하는 이층정 약제학적 복합제제 |
EP2468258A1 (en) * | 2010-12-22 | 2012-06-27 | LEK Pharmaceuticals d.d. | Process for the preparation of a pharmaceutical composition comprising a low soluble pharmaceutically active ingredient |
WO2013066279A1 (en) * | 2011-10-13 | 2013-05-10 | Mahmut Bilgic | Solid dosage forms comprising ezetimibe |
PT2844233T (pt) * | 2012-05-01 | 2020-06-25 | Althera Life Sciences Llc | Formulação de comprimido oral que consiste numa combinação fixa de rosuvastatina e ezetimiba para o tratamento de hiperlipidemia e doenças cardiovasculares |
AU2013264518B2 (en) * | 2012-05-22 | 2016-02-11 | Kuhnil Pharm. Co., Ltd. | Multilayer coating form of orally administered pharmaceutical composition containing omega-3 fatty acid or alkyl ester thereof and statin based drug |
MX2012014970A (es) * | 2012-12-18 | 2013-08-27 | Hetlabs Mexico S A De C V | Composiciones farmaceuticas que comprenden ezetimiba y rosuvastatina de calcio amorfo novedoso. |
KR102240429B1 (ko) * | 2013-05-06 | 2021-04-15 | 한미약품 주식회사 | 로수바스타틴 또는 이의 약학적으로 허용되는 염이 함유된 필름 코팅층을 포함하는 복합 제형 |
-
2014
- 2014-06-11 KR KR1020140071081A patent/KR20150079373A/ko unknown
- 2014-12-29 UY UY0001035932A patent/UY35932A/es not_active Application Discontinuation
- 2014-12-29 KR KR1020140192374A patent/KR20150079454A/ko active Search and Examination
- 2014-12-29 TW TW103146067A patent/TWI655944B/zh not_active IP Right Cessation
- 2014-12-30 CR CR20160293A patent/CR20160293A/es unknown
- 2014-12-30 MX MX2016008725A patent/MX2016008725A/es unknown
- 2014-12-30 WO PCT/KR2014/013087 patent/WO2015102400A1/en active Application Filing
- 2014-12-30 MY MYPI2016000980A patent/MY187637A/en unknown
- 2014-12-30 AR ARP140104955A patent/AR098996A1/es unknown
- 2014-12-30 EP EP14876988.8A patent/EP3089739A4/en not_active Withdrawn
- 2014-12-30 RU RU2016123828A patent/RU2683937C2/ru active
- 2014-12-30 SG SG10201805657PA patent/SG10201805657PA/en unknown
- 2014-12-30 PE PE2016000976A patent/PE20161072A1/es unknown
- 2014-12-30 CA CA2933178A patent/CA2933178A1/en not_active Abandoned
- 2014-12-30 US US15/108,940 patent/US10434067B2/en not_active Expired - Fee Related
- 2014-12-30 JP JP2016537529A patent/JP2017500303A/ja active Pending
- 2014-12-30 UA UAA201605792A patent/UA117685C2/uk unknown
- 2014-12-30 AU AU2014374552A patent/AU2014374552B2/en not_active Expired - Fee Related
- 2014-12-30 CN CN201480071651.8A patent/CN105873571B/zh active Active
-
2016
- 2016-06-09 ZA ZA2016/03934A patent/ZA201603934B/en unknown
- 2016-06-17 PH PH12016501196A patent/PH12016501196A1/en unknown
- 2016-06-24 DO DO2016000159A patent/DOP2016000159A/es unknown
- 2016-06-28 NI NI201600093A patent/NI201600093A/es unknown
- 2016-06-28 CL CL2016001654A patent/CL2016001654A1/es unknown
- 2016-06-28 SV SV2016005236A patent/SV2016005236A/es unknown
- 2016-06-28 GT GT201600137A patent/GT201600137A/es unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
NI201600093A (es) | Formulación compuesta para administración oral que comprende ezetimibe y rosuvastatina | |
PH12016501122A1 (en) | Delayed release compositions of linaclotide | |
PH12015501595A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
PH12015501598A1 (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
WO2014205389A8 (en) | Nuclear transport modulators and uses thereof | |
SG10201810985XA (en) | Tofacitinib oral sustained release dosage forms | |
MY188450A (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
MX368903B (es) | Compuestos terapéuticos y sus usos en el tratamiento de enfermedades proliferativas. | |
JOP20150154B1 (ar) | صيغة مادة مركبة للإعطاء عن طريق الفم تشتمل على إزيتمايب ورسيوفاستاتين وعملية تحضيرها | |
UA117032C2 (uk) | Селективний інгібітор фосфатидилінозитол-3-кінази-гамма | |
GT201500035A (es) | Composición farmacéutica oral en forma de microesferas y proceso de elaboración | |
WO2014114255A3 (zh) | 一种定位速释生物粘附剂及应用 | |
NZ723631A (en) | Nanosuspension of natural materials and preparation method thereof | |
DOP2014000269A (es) | Nueva dosificación y formulación | |
MX366829B (es) | Composiciones y formas de dosificacion de itraconazol y metodos de uso de las mismas. | |
MX2015009891A (es) | Composiciones farmaceuticas que comprenden particulas cristalinas de multicomponentes adecuadas para usar en terapia de inhalacion. | |
IN2013MU01177A (es) | ||
AU2014226192A8 (en) | Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles | |
PL408608A1 (pl) | Trwała stała kompozycja farmaceutyczna cytyzyny oraz sposób jej wytwarzania | |
AR093252A1 (es) | Composicion farmaceutica oral utilizada como antiparasitaria y antidiarreica y procesos para prepararla | |
ECSP19037610A (es) | Comprimido compuesto oral que comprende ezetimiba y rosuvastatina | |
WO2013111013A3 (en) | Methods for treating alzheimer's disease by administering certain synthetic compounds | |
IN2013MU03428A (es) | ||
ECSP17008187A (es) | Formas de dosificación farmacéutica | |
UA80535U (uk) | Фармацевтична композиція для лікування сексуальної дисфункції |